What taper schedule should be used to discontinue bupropion (Bupropion XL) 300 mg after two years of therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bupropion XL 300mg Taper Schedule After 2 Years

For patients discontinuing bupropion XL 300mg after 2 years of therapy, reduce the dose to 150mg once daily for at least 1-2 weeks before complete discontinuation. 1

FDA-Approved Tapering Protocol

The FDA drug label for bupropion XL explicitly states: "When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL), 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation." 1

This is the only evidence-based taper schedule specifically validated for bupropion XL and should be followed as the standard approach.

Practical Implementation

Standard Taper (Low-Risk Patients)

  • Week 1-2: Reduce from 300mg to 150mg once daily in the morning
  • After Week 2: Discontinue completely

Extended Taper (Higher-Risk Patients)

For patients with:

  • History of difficult medication discontinuations
  • Significant anxiety or mood symptoms
  • Concerns about withdrawal effects

Consider:

  • Week 1-2: 300mg to 150mg once daily
  • Week 3-4: Continue 150mg daily (extended stabilization)
  • After Week 4: Discontinue

Alternatively, for very cautious tapering:

  • Week 1-2: 300mg to 150mg daily
  • Week 3-4: 150mg every other day
  • After Week 4: Discontinue

Key Clinical Considerations

Bupropion has minimal withdrawal syndrome risk. Unlike SSRIs or SNRIs, bupropion does not cause significant discontinuation symptoms in most patients. The FDA label mentions tapering primarily to minimize potential rebound effects rather than severe withdrawal 1.

Timing of administration matters. Continue taking the morning dose throughout the taper to minimize insomnia risk 2, 3.

Monitor for mood changes. While bupropion withdrawal is generally mild, watch for:

  • Return of depressive symptoms (relapse vs. withdrawal)
  • Increased irritability
  • Sleep disturbances
  • Fatigue

These typically emerge within 1-3 days if they occur 4.

Common Pitfalls to Avoid

Do not abruptly discontinue. Even though bupropion has lower withdrawal risk than other antidepressants, the FDA specifically recommends dose reduction before stopping 1.

Do not confuse withdrawal with relapse. If depressive symptoms emerge during or after tapering, distinguish between:

  • Withdrawal: Typically resolves within days to 1-2 weeks
  • Relapse: Persistent symptoms requiring treatment resumption

Do not use overly complex tapers. Unlike medications with severe withdrawal syndromes (benzodiazepines, opioids), bupropion does not require the months-long hyperbolic tapers described for other antidepressants 4, 5, 6. The simple two-step taper (300mg → 150mg → stop) is sufficient for most patients.

Special Populations

Hepatic impairment: Patients already on reduced dosing schedules due to liver disease should taper even more gradually, potentially extending the 150mg phase to 3-4 weeks 1.

Renal impairment: Similar caution applies; consider extending the 150mg stabilization period 1.

Concurrent psychiatric medications: If the patient is on other psychotropic medications, coordinate the taper with their prescriber to avoid compounding effects.

When to Pause or Reverse the Taper

If significant mood destabilization occurs:

  • Pause at 150mg for 2-4 additional weeks
  • Return to 300mg if clear relapse occurs (not just mild transient symptoms)
  • Reassess the appropriateness of discontinuation with the patient

The evidence strongly supports that most patients can successfully discontinue bupropion XL using the straightforward FDA-recommended taper without significant complications 1.

References

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Guideline

prevention and control of seasonal influenza with vaccines.

MMWR Recommendations and Reports, 2016

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.